FTC Seeks Information on Amgen Deal

Amgen Inc., which is acquiring rival Immunex Corp., said the two companies received a request for additional information from the Federal Trade Commission about their $16-billion combination.

The two drug makers “intend to respond promptly to the information request, which is a matter of routine and customary in these sorts of matters,” said Amgen spokesman Jeff Richardson. Amgen and Immunex said they still expect that the merger will be completed during the second half of 2002. It is the second request made by the FTC.